GL Ventures, LAV co-lead $50m Series A funding in vision therapy firm Elumninex

Ophthalmic therapy developer Elumninex Biosciences has secured a $50 million Series A round of financing co-led by Hillhouse Capital’s VC arm GL Ventures, Shanghai-based biomedical VC firm Lilly Asia Ventures (LAV), and Quan Capital, as per a company statement on Tuesday.